DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (“Neos” or “the Company”), a pharmaceutical company with three late-stage extended-release (“XR”) product candidates for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results